MatchTx LLC

MatchTx is a SaaS software. company that provides a big data predictive genome analytics. A.I. solution for the oncology industry. For the pharmaceutical and drug development industry, the goal is to use more of the genomic data in order to reduce cancer drug development costs. For clinical care, the software is intended to provide clinical decision support by predicting how a patient will respond to a treatment based on how the most genetically similar tumors previously responded. Today nearly every cancer patient gets their tumor genome sequenced as standard of care, but patients are matched to treatments based on at best a very limited amount of information of that genetic data. The result of mismatches is suffering for patients and high expense for the Pharma companies developing new drugs. MatchTx uses deep genomic data analytics to match tumors to the most similar previous ones with known outcomes to better predict how the current patient will do on a drug or trial – for better patient and clinical trial outcomes. MatchTx is AWS-hosted SaaS software that has been validated on multiple large cancer data sets. Typical applications are patient outcome predictions, patient cohort matching, and biomarker discovery. The proprietary MatchTx alogorithms are intended for situations where there are more biomarkers than subjects - this is where traditional statistics fail, and machine learning tends to over-train on reference sets. MatchTX analyzes all of the common single and combination (such as GeneA mut/GeneB wt) biomarkers to identify all the contribute to predicting outcome in reference sets, and then uses the set of predictive signatures to match new patients to the most genetically similar patient tumors in the reference set - and then infers outcome from these. Thus if the best matched tumors responded well to a treatment, that drug or trial is likely fine for the patient; however poor predictions suggest a different drug or clinical trial.